Our findings not only put forth a heretofore unrecognized mechanism underlying the regulation of YAP signaling by TET2, but also identify TET2 as a potential biomarker for predicting sorafenib resistance of HCC, providing a possible route for precision therapy in clinic. Here, TET2 is linked to hepatocellular carcinoma.